Skip to content
10-Q

Quarterly Report

MERRIMACK PHARMACEUTICALS INC

0000950170-23-017932

← back to feed
Filed
May 4, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · May 1, 2023 14.26M sh
Cash And Equivalents Q1 2023 · Mar 31, 2023 $19.4M
Cash And Equivalents Q1 2023 · Dec 31, 2022 $19.44M
Current Liabilities Q1 2023 · Mar 31, 2023 $463K
Current Liabilities Q1 2023 · Dec 31, 2022 $589K
Total Liabilities Q1 2023 · Mar 31, 2023 $463K
Total Liabilities Q1 2023 · Dec 31, 2022 $589K
Current Assets Q1 2023 · Mar 31, 2023 $19.63M
Current Assets Q1 2023 · Dec 31, 2022 $19.83M
Total Assets Q1 2023 · Mar 31, 2023 $19.64M
Total Assets Q1 2023 · Dec 31, 2022 $19.84M
Shares Diluted Q1 2023 · Mar 31, 2022 13.41M sh
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$354K
Stockholders Equity Q1 2023 · Mar 31, 2022 $14.08M
Stockholders Equity Q1 2023 · Dec 31, 2021 $14.19M
Eps Diluted Q1 2023 · Mar 31, 2022 −$0.01
Eps Basic Q1 2023 · Mar 31, 2022 −$0.01
Operating Income Q1 2023 · Mar 31, 2022 −$132K